GSK Inks $500M Oncology Deal with Adaptimmune

Feb 03, 2016

Financial Times

GlaxoSmithKline has announced a $500 million expanded strategic collaboration agreement with clinical stage biopharmaceutical company, Adaptimmune Therapeutics.

Adaptimmune Therapeutics specializes in the use of T-cell receptor (TCR) engineered T-cell therapy to treat cancer. GSK and Adaptimmune are partnering to push Adaptimmune’s engineered T-cell therapy — treatment that modifies a patient’s immune cells to detect and destroy cancer — into pivotal clinical trials sooner than expected.

After selling its oncology portfolio to Novartis last year, this partnership asserts GSK's continued commitment cell therapies, considered by many to be the next generation of cancer treatment.

Read the Financial Times article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments